Evidence map›Paper›PMID 42775166›Full record

ArticleSage open chronic disease

Hepatitis C elimination protocol in Cantabria: Updated regional strategy and outcomes from a population-based cohort and opportunistic screening programs.

Joaquin Cabezas, Marta Alonso-Peña, Antonio Cuadrado, Lorena Cayón, Reinhard Wallmann, Ana Tejerina Puente, Gonzalo Perez-Roji, María Pía Roiz-Mesones, Javier Crespo, Task Force for the Elimination of Hepatitis C in Cantabria

Abstract read
In one paragraph

Article in Sage open chronic disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joaquin CabezasGastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute, Marqués de Valdecilla University Hospital, Santander, Spain.ORCID https://orcid.org/0000-0003-0012-484X
Marta Alonso-PeñaGastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute, Marqués de Valdecilla University Hospital, Santander, Spain.ORCID https://orcid.org/0000-0003-0934-2202
Antonio CuadradoGastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute, Marqués de Valdecilla University Hospital, Santander, Spain.
Lorena CayónGastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute, Marqués de Valdecilla University Hospital, Santander, Spain.
Reinhard WallmannDepartment of Preventive Medicine, Marqués de Valdecilla University Hospital, Santander, Spain.
Ana Tejerina PuenteUnit of Pediatrics, Health Center La Marina (Santander), Cantabrian Health Service, Santander, Spain.
Gonzalo Perez-RojiEmergency Department, Marqués de Valdecilla University Hospital, Santander, Spain.
María Pía Roiz-MesonesMicrobiology Department, Marqués de Valdecilla University Hospital, Valdecilla Research Institute, Santander, Spain.
Javier CrespoGastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute, Marqués de Valdecilla University Hospital, Santander, Spain.ORCID https://orcid.org/0000-0001-8248-0172
Task Force for the Elimination of Hepatitis C in Cantabria

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thanks to the emergence of direct-acting antiviral agents, Hepatitis C (hepatitis C virus (HCV)) elimination is a real possibility. In 2016, the World Health Organization established a global strategy with the aim of achieving HCV elimination by 2030. However, the actual implementation of this strategy within healthcare systems worldwide has proven challenging, and the COVID-19 pandemic nearly completely halted HCV elimination programs. Seroprevalence studies in the general population attending health centers in Spain place us as a low-prevalence country, but recent reports have shown that the Emergency Department and hospital population show significantly higher prevalence rates, suggesting that studies in the general population may underestimate the true prevalence, especially in vulnerable people. Thus, HCV screening should be implemented through a combination of approaches: population-based programs, self-referral options, and opportunistic testing during any healthcare encounter. Here, we summarize the main updates to the measures adopted in the Strategy for the Elimination of Hepatitis C in Cantabria, a region in northern Spain, so that they can serve as inspiration for other regions. The update prespecifies primary operational and virological endpoints (coverage, linkage‑to‑care, time‑to‑treatment, and sustained virological response 12 (SVR12)), and secondary clinical outcomes, and it includes a pragmatic economic assessment (cost per diagnosis/SVR and budget impact).

Indexed as

direct-acting antiviralselimination strategieshepatitis C viruspopulation screeningpublic health policies

Identifiers

PMID42775166
PMCPMC13595323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.